Halda
Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials
Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing
Halda Therapeutics Secures $126M in Series B Funding to Advance Next-Gen Oral TACs
Halda Therapeutics, Series B funding, next-gen oral TACs, biotech, clinical trials, prostate cancer